American Renal Associates Holdings (American Renal Associates Holdings) Cash-to-Debt : 0.18 (As of Sep. 2020)

View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. American Renal Associates Holdings's cash to debt ratio for the quarter that ended in Sep. 2020 was 0.18.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, American Renal Associates Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2020.

The historical rank and industry rank for American Renal Associates Holdings's Cash-to-Debt or its related term are showing as below:

ARA's Cash-to-Debt is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.32
* Ranked among companies with meaningful Cash-to-Debt only.

American Renal Associates Holdings Cash-to-Debt Historical Data

The historical data trend for American Renal Associates Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

American Renal Associates Holdings Cash-to-Debt Chart

American Renal Associates Holdings Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

0.13

0.18

0.13

0.10

0.05

American Renal Associates Holdings Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Cash-to-Debt	Get a 7-Day Free Trial															0.08	0.05	0.08	0.18	0.18

Competitive Comparison of American Renal Associates Holdings's Cash-to-Debt

For the Diagnostics & Research subindustry, American Renal Associates Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Renal Associates Holdings's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's Cash-to-Debt falls into.

American Renal Associates Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

American Renal Associates Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	34.494	/	(60.84	+	672.627)
	=	0.05

American Renal Associates Holdings's Cash to Debt Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	126.737	/	(59.644	+	662.831)
	=	0.18

American Renal Associates Holdings (NYSE:ARA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

American Renal Associates Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of American Renal Associates Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915

Website

https://www.americanrenal.com

American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.

Executives

Don E Williamson	officer: EVP, Chief Operating Officer	500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola	officer: VP and General Counsel	AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci	director, officer: Chief Executive Officer	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal	director, officer: President	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber	director	C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar	director	1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish	director	C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer	director	9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller	director	FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson	director	OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher	officer: Former VP & CFO	500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers	officer: Interim CFO and Interim CAO	500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa	officer: VP and General Counsel	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan	director	401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox	officer: VP & Chief Financial Officer	C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915